

Diabetic Ketoacidosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others) By Region & Competition, 2020-2030F

Market Report | 2025-05-16 | 185 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

Report description:

Market Overview

The Global Diabetic Ketoacidosis (DKA) Market was valued at USD 3.24 Billion in 2024 and is expected to reach USD 4.42 Billion by 2030, growing at a CAGR of 5.35% during the forecast period. DKA is a severe, potentially life-threatening complication of diabetes, particularly Type 1, characterized by elevated blood glucose levels and ketone buildup. The market includes a broad range of pharmaceuticals, diagnostics, and medical devices designed to prevent and manage DKA episodes effectively. With diabetes affecting one in ten adults globally-as reported by the International Diabetes Federation in 2022-DKA remains a pressing concern in clinical settings. Key contributors to market growth include rising diabetes incidence, growing adoption of advanced glucose monitoring technologies, and innovations in insulin therapy. Developments such as ultra-rapid-acting insulins and integrated insulin delivery systems have improved treatment outcomes, while innovations in continuous glucose monitoring and point-of-care diagnostics have enhanced disease management and early DKA detection. As a result, the market is evolving quickly to meet the increasing demand for effective DKA solutions across diverse healthcare environments.

Key Market Drivers

Rising Prevalence of Diabetes

The growing global burden of diabetes is a major factor fueling the expansion of the DKA market. According to the International Diabetes Federation, 537 million individuals were living with diabetes in 2021, a figure projected to rise to 643 million by 2030. Among these, patients with Type 1 diabetes are especially vulnerable to DKA, emphasizing the need for comprehensive management strategies. Factors contributing to the rising incidence include sedentary lifestyles, poor dietary habits, urbanization, and genetic susceptibility. In the United States alone, the CDC reports over 34 million people with diabetes, both diagnosed and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

undiagnosed. With prediabetes also on the rise, the risk of DKA episodes is increasing, creating sustained demand for effective monitoring tools, insulin therapy, and emergency care solutions.

Key Market Challenges

Limited Access to Healthcare Services

Access to healthcare services remains a critical challenge in addressing DKA, particularly in low-income and rural regions. In these areas, limited availability of trained medical personnel, diagnostic tools, and essential medicines such as insulin hampers effective diabetes management. As a result, patients often experience delayed diagnosis and poor glycemic control, increasing their risk of developing DKA. The high cost of diabetes care—including insulin, blood glucose monitors, and regular medical supervision—further restricts access, forcing many to compromise their treatment. This disparity not only leads to increased hospitalizations and complications but also highlights the need for more equitable and affordable healthcare infrastructure to prevent DKA globally.

Key Market Trends

Technological Advancements in Glucose Monitoring

Technological innovation in glucose monitoring is transforming the landscape of DKA prevention and management. Continuous Glucose Monitoring (CGM) systems provide real-time insights into blood glucose trends, helping patients and providers detect early signs of hyperglycemia. This allows for timely intervention and reduces the likelihood of DKA episodes. CGM systems offer advantages such as trend analysis, alert notifications, and historical data tracking, which support improved insulin dosing and lifestyle adjustments. These features empower patients to manage their condition more proactively. In parallel, the rise of smart insulin pumps and integrated digital health platforms is enhancing the precision and convenience of insulin delivery, contributing to better DKA management outcomes.

Key Market Players

- Novo Nordisk AS
- Baxter Healthcare Corporation
- B. Braun Medical Inc.
- ICU Medical, Inc.
- Pfizer Inc.
- Merit Pharmaceutical
- SteriCare Solutions
- Soxa Formulations & Research (Pvt.) Ltd
- BD company
- Fresenius Kabi USA

Report Scope:

In this report, the Global Diabetic Ketoacidosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

- Diabetic Ketoacidosis Market, By Treatment:

- o Insulin Therapy
- o Electrolyte Replacement
- o Fluid Replacement

- Diabetic Ketoacidosis Market, By End User:

- o Hospitals & Clinics
- o Ambulatory Care Centers
- o Others

- Diabetic Ketoacidosis Market, By Region:

- o North America
 - United States
 - Canada
 - Mexico
- o Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- France
- United Kingdom
- Italy
- Germany
- Spain
- o Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- o South America
- Brazil
- Argentina
- Colombia
- o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Ketoacidosis Market.

Available Customizations:

Global Diabetic Ketoacidosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

- Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Global Diabetic Ketoacidosis Market Outlook
 - 4.1. Market Size & Forecast
 - 4.1.1. By Value
 - 4.2. Market Share & Forecast
 - 4.2.1. By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement)
 - 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
 - 4.2.3. By Region
 - 4.2.4. By Company (2024)
 - 4.3. Market Map
 - 4.3.1. By Treatment
 - 4.3.2. By End User
 - 4.3.3. By Region
- 5. Asia Pacific Diabetic Ketoacidosis Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Treatment
 - 5.2.2. By End User
 - 5.2.3. By Country
 - 5.3. Asia Pacific: Country Analysis
 - 5.3.1. China Diabetic Ketoacidosis Market Outlook
 - 5.3.1.1. Market Size & Forecast
 - 5.3.1.1.1. By Value
 - 5.3.1.2. Market Share & Forecast
 - 5.3.1.2.1. By Treatment
 - 5.3.1.2.2. By End User
 - 5.3.2. India Diabetic Ketoacidosis Market Outlook
 - 5.3.2.1. Market Size & Forecast
 - 5.3.2.1.1. By Value
 - 5.3.2.2. Market Share & Forecast
 - 5.3.2.2.1. By Treatment
 - 5.3.2.2.2. By End User
 - 5.3.3. Australia Diabetic Ketoacidosis Market Outlook
 - 5.3.3.1. Market Size & Forecast
 - 5.3.3.1.1. By Value
 - 5.3.3.2. Market Share & Forecast
 - 5.3.3.2.1. By Treatment
 - 5.3.3.2.2. By End User
 - 5.3.4. Japan Diabetic Ketoacidosis Market Outlook
 - 5.3.4.1. Market Size & Forecast
 - 5.3.4.1.1. By Value
 - 5.3.4.2. Market Share & Forecast
 - 5.3.4.2.1. By Treatment
 - 5.3.4.2.2. By End User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.3.5. South Korea Diabetic Ketoacidosis Market Outlook
 - 5.3.5.1. Market Size & Forecast
 - 5.3.5.1.1. By Value
 - 5.3.5.2. Market Share & Forecast
 - 5.3.5.2.1. By Treatment
 - 5.3.5.2.2. By End User
- 6. Europe Diabetic Ketoacidosis Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Treatment
 - 6.2.2. By End User
 - 6.2.3. By Country
 - 6.3. Europe: Country Analysis
 - 6.3.1. France Diabetic Ketoacidosis Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Treatment
 - 6.3.1.2.2. By End User
 - 6.3.2. Germany Diabetic Ketoacidosis Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Treatment
 - 6.3.2.2.2. By End User
 - 6.3.3. Spain Diabetic Ketoacidosis Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Treatment
 - 6.3.3.2.2. By End User
 - 6.3.4. Italy Diabetic Ketoacidosis Market Outlook
 - 6.3.4.1. Market Size & Forecast
 - 6.3.4.1.1. By Value
 - 6.3.4.2. Market Share & Forecast
 - 6.3.4.2.1. By Treatment
 - 6.3.4.2.2. By End User
 - 6.3.5. United Kingdom Diabetic Ketoacidosis Market Outlook
 - 6.3.5.1. Market Size & Forecast
 - 6.3.5.1.1. By Value
 - 6.3.5.2. Market Share & Forecast
 - 6.3.5.2.1. By Treatment
 - 6.3.5.2.2. By End User
 - 7. North America Diabetic Ketoacidosis Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2. Market Share & Forecast
 - 7.2.1. By Treatment
 - 7.2.2. By End User
 - 7.2.3. By Country
- 7.3. North America: Country Analysis
 - 7.3.1. United States Diabetic Ketoacidosis Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Treatment
 - 7.3.1.2.2. By End User
 - 7.3.2. Mexico Diabetic Ketoacidosis Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Treatment
 - 7.3.2.2.2. By End User
 - 7.3.3. Canada Diabetic Ketoacidosis Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Treatment
 - 7.3.3.2.2. By End User
- 8. South America Diabetic Ketoacidosis Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Treatment
 - 8.2.2. By End User
 - 8.2.3. By Country
 - 8.3. South America: Country Analysis
 - 8.3.1. Brazil Diabetic Ketoacidosis Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Treatment
 - 8.3.1.2.2. By End User
 - 8.3.2. Argentina Diabetic Ketoacidosis Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Treatment
 - 8.3.2.2.2. By End User
 - 8.3.3. Colombia Diabetic Ketoacidosis Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.3.2.1. By Treatment
- 8.3.3.2.2. By End User
- 9. Middle East and Africa Diabetic Ketoacidosis Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Treatment
 - 9.2.2. By End User
 - 9.2.3. By Country
 - 9.3. MEA: Country Analysis
 - 9.3.1. South Africa Diabetic Ketoacidosis Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Treatment
 - 9.3.1.2.2. By End User
 - 9.3.2. Saudi Arabia Diabetic Ketoacidosis Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Treatment
 - 9.3.2.2.2. By End User
 - 9.3.3. UAE Diabetic Ketoacidosis Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Treatment
 - 9.3.3.2.2. By End User
 - 9.3.4. Egypt Diabetic Ketoacidosis Market Outlook
 - 9.3.4.1. Market Size & Forecast
 - 9.3.4.1.1. By Value
 - 9.3.4.2. Market Share & Forecast
 - 9.3.4.2.1. By Treatment
 - 9.3.4.2.2. By End User
- 10. Market Dynamics
 - 10.1. Drivers
 - 10.2. Challenges
- 11. Market Trends & Developments
 - 11.1. Recent Developments
 - 11.2. Product Launches
 - 11.3. Mergers & Acquisitions
- 12. Global Diabetic Ketoacidosis Market: SWOT Analysis
- 13. Porter's Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.5. Threat of Substitute Product
- 14. Competitive Landscape
 - 14.1. Novo Nordisk AS
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Products & Services
 - 14.1.4. Financials (In case of listed)
 - 14.1.5. Recent Developments
 - 14.1.6. SWOT Analysis
 - 14.2. Baxter Healthcare Corporation
 - 14.3. B. Braun Medical Inc.
 - 14.4. ICU Medical, Inc.
 - 14.5. Pfizer Inc.
 - 14.6. Merit Pharmaceutical
 - 14.7. SteriCare Solutions
 - 14.8. Soxa Formulations & Research (Pvt.) Ltd
 - 14.9. BD company
 - 14.10. Fresenius Kabi USA
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Diabetic Ketoacidosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others) By Region & Competition, 2020-2030F

Market Report | 2025-05-16 | 185 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Date

2026-03-17

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com